Literature DB >> 8204354

The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2.

M E Gore1, E Galligioni, C W Keen, R Sorio, E M Loriaux, H C Grobben, C R Franks.   

Abstract

Between March 1989 and June 1990, 133 patients were treated with interleukin 2 (rIL-2) for metastatic renal cell carcinoma (RCC) in a multicentre open non-randomised study. The results show an objective response rate of 14% (95% confidence interval 8-21) with 4 patients achieving a complete remission. This is in keeping with the data from previous studies using rIL-2 by continuous infusion. It is of interest that 87% of objective responses occurred in hospitals that entered 5 or more patients.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8204354     DOI： 10.1016/0959-8049(94)90251-8

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  3 in total

1.  Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.

Authors:  C M van Herpen; R L Jansen; W H Kruit; K Hoekman; G Groenewegen; S Osanto; P H De Mulder
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

2.  A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma.

Authors:  F Y Ahmed; G A Leonard; R A'Hern; A E Taylor; A Lorentzos; H Atkinson; J Moore; M C Nicolson; P G Riches; M E Gore
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

3.  Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma.

Authors:  P F Geertsen; M E Gore; S Negrier; J M Tourani; H von der Maase
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.